China Medical Device PMS Services
Effective post-market surveillance (PMS) is essential for maintaining the safety and performance of medical devices after they have been introduced to the Chinese market. Under China's evolving medical device regulation, the National Medical Products Administration (NMPA) mandates that In-Vitro Diagnostic (IVD) and medical device manufacturers establish and maintain a compliant PMS system to ensure long-term safety, effectiveness, and market access.
.avif)
What is Post-Market Surveillance (PMS)?
Post-market surveillance (PMS) refers to the ongoing process of monitoring the clinical performance and device performance of medical devices and IVDs once they are commercially available. In contrast to pre-market clinical trials, PMS collects real-world clinical data through user feedback, adverse events, and market observations to ensure ongoing medical device safety.
In China, a robust post-market surveillance framework is legally required and forms an essential part of the broader quality management system. It plays a critical role in identifying risks that could lead to serious adverse health consequences or serious incidents, particularly for high-risk Class III devices.
Regulatory Overview of PMS in China
The NMPA has significantly expanded its focus on post-market surveillance, introducing regulations that emphasize real-world data, proactive risk control, and continuous compliance. Under these regulations, manufacturers must:
Manufacturers have specific responsibilities under NMPA regulations to ensure compliance with these requirements, including the implementation of post-market surveillance plans and maintaining the safety and performance of medical devices.
Noncompliance with these regulatory requirements may lead to enforcement actions, including certificate suspension or market withdrawal.
Core Components of a PMS System under the NMPA
To effectively meet China’s PMS requirements, IVD and medical device manufacturers must implement a structured system encompassing the following components:
1. Adverse Event Monitoring
The NMDAEM System is monitored to identify potential health risks early, especially for events that could result in adverse health consequences. AE reports must be reviewed, translated if necessary, and submitted to NMPA within prescribed timelines.
2. PRER Reports
Manufacturers of Class II and III devices must submit Periodic Risk Evaluation Reports (PRERs) summarizing cumulative risk data, trend analyses, and resulting risk mitigations. Class I manufacturers must compile PRERs and ensure the Legal Agent files them in preparation for local inspections.
3. Corrective & Preventive Actions (CAPA)
CAPAs are initiated in response to identified issues. These actions must address root causes, be well-documented, and include follow-up monitoring to verify effectiveness.
4. Label & IFU Compliance
Chinese-language labels and Instructions for Use (IFUs) must be reviewed to confirm they meet the NMPA’s content and formatting standards, including accurate legal agent and manufacturer details.
5. UDI & Traceability
For devices subject to China’s UDI regulation, manufacturers must maintain updated UDI-DI codes in the NMPA database and ensure traceability throughout the supply chain.
6. Annual Reports
Annual reports summarize yearly Quality Management System (QMS) self-inspections and Periodic Risk Evaluation Reports (PRER) for medical devices, with requirement cycles varying by product class.
7. Integration with QMS
PMS processes should be embedded within the organization’s certified QMS to ensure a seamless approach to compliance and continuous improvement.
Common Challenges in China PMS Compliance
PMS implementation in China is not without obstacles. IVD and medical device companies often encounter:
Solutions include:
Post-Market Surveillance as Part of a QMS
Embedding PMS into the QMS framework ensures consistent, organization-wide awareness of safety obligations. A QMS is essential for meeting international standards like ISO 13485:2016, ensuring compliance with regulatory obligations. This alignment supports:
Many manufacturers report better regulatory performance and reduced product release delays after integrating PMS activities into their core QMS.
For medical device companies in China, post-market surveillance is more than a compliance requirement, it is a strategic pillar of safe, effective, and sustainable operations. By aligning with NMPA’s PMS framework and integrating surveillance activities into your QMS, you enhance regulatory readiness, improve product safety, and strengthen patient trust. Active monitoring and a proactive, well-documented PMS system are the foundation for long-term success in the Chinese medical device market.
Our Post-Market Surveillance Services for NMPA Compliance
To help you perform post market surveillance activities for China, below is a non-exhaustive list of services we offer. We also help you build a proactive PMS strategy:
QMS Self-Assessment Support
Annual report reminders, bilingual templates, review, and submission to NMPA.
Periodic Risk Evaluation (PRER)
Guidance, review, and timely submission of PRERs in line with NMPA requirements.
Adverse Event Monitoring & Response
NMDAEM system monitoring on each working day, with full AE handling, submission, and tracking.
Annual AE Summary & Analysis
Yearly review and reporting of all adverse events to support risk management.
Regulatory News & Updates
Regular alerts on new NMPA regulations and standards affecting your product certificates.
Recall & UDI Support
Representation during recalls and assistance with UDI-DI transfers in the NMPA database.
Label & IFU Compliance Checks
Review of Chinese labeling and IFU content to meet NMPA standards.
Insurance & Procurement Reporting
Submission of AE and risk reports for medical insurance and centralized bidding.
It is crucial for any company to manage and improve their PMS processes efficiently, as this impacts the overall safety and effectiveness of the devices they produce.
Explore Related Services
Whether you’re just starting out or are a blue-chip, access our wide range of services and solutions to help your business thrive. We also help your company conduct postmarket surveillance to ensure regulatory compliance and device safety.
China Medical Device Registration
We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal market entry pathway, and helping you through the whole process.
NMPA Legal Agent
We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements.
China Clinical Trials
You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China. Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.
NMPA Clinical Evaluation Report
Clinical Evaluation Reports can avoid the need for a China clinical trial in some instances. Our experts can advise and prepare NMPA compliant CERs.
Drug Device Combination Products
We assist with the classification, registration, and compliance of combination products in China, whether drug or device led.
NMPA Type Testing
Our on-site test engineers coordinate and supervise type tests of your medical devices in NMPA-accredited laboratories.
China Medical Device Quality Compliance
We help you achieve and ensure ongoing compliance with Chinese requirements.
Our experts prepare and assist you for official NMPA inspections.
Regulatory Outsourcing
If you are seeking specific specialist expertise or have ongoing resource-intensive needs, we have a variety of solutions to meet your needs.
